Clinical trials: Cognitive Intervention
Aging, Mortality
Longevity Metrics AI/ML Development Study
This study builds AI models that score diagnostic screening tests, and that predict screening results, clinical judgment, and life expectancy.
- Conditions
- Aging, Mortality, Cardiovascular Disease Prevention, Metabolic Syndrome
- Trial name
- NCT07808619
- Testing
- AIML scored health screening battery
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Longevity Metrics, Inc.
Alzheimer Disease, Dementia
Reducing Dementia Risk With Digital Health Coaching
The Digital Cognitive Multi-domain Alzheimer's Risk Velocity (DC MARVEL) study is a 2-year randomized controlled trial on dementia prevention.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- DC-MARVEL (NCT04559789)
- Testing
- MindMate + Health Coaching, Health Education
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Neurotrack Technologies, Inc.
Mild Cognitive Impairment
Effectiveness and Safety of a Digitally Based Multidomain Intervention for Mild Cognitive Impairment
This study is designed to evaluate the preliminary effectiveness and safety of a digitally based multidomain intervention in patients with MCI.
- Trial name
- NCT05059353
- Testing
- Digitally based multidomain intervention
- Where
- Singapore
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Neuroglee Therapeutics
Alzheimer Disease, Dementia
ADVANCE Study: Alzheimer Disease eVAluation iN Clinical PracticE
In 1906, Dr. Alois Alzheimer first described the disease that later took his name. Today, 100 years later, 24 million people worldwide suffer from Alzheimer's disease or other dementias.
- Conditions
- Alzheimer Disease, Dementia, Cognitive Disorders
- Trial name
- ADVANCE (NCT01772095)
- Where
- Greece
- Volunteers
- 389 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Sleep
Nutritional Intervention to Improve Sleep Quality and Improve Next-day Mood and Cognitive Benefits
The study aim to test the effect of a meal complement to be taken in combination with an evening meal with a glycemic load of 55, to improve sleep quality.
- Trial name
- NCT05372900
- Testing
- Test Product, Control Product
- Where
- Singapore
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Alcohol Use Disorder
Integrated Digital Intervention for Alcohol Use Disorder
This study is a two-arm randomized clinical trial comparing the Quit Genius intervention for alcohol use disorder (QG-A) to usual care (TAU), comprising medical management of alcohol use disorders with pharmacotherapy.
- Trial name
- NCT05748639
- Testing
- Mobile health application, Medical Management
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- Quit Genius
Traumatic Brain Injury
To Compare the Effect of Receiving the Technology-based Training Along With the Conventional Therapy to the Conventional Therapy Alone on Executive Functions Among People With Traumatic Brain Injury With Mild to Moderate Cognitive Deficit
The goal of this clinical trial is to compare the effect of receiving the technology-based training along with the conventional therapy to the conventional therapy alone on executive functions among people with traumatic brain…
- Trial name
- NCT06080269
- Testing
- technology based intervention along with conventional therapy, conventional therapy alone
- Where
- Qatar
- Volunteers
- 60 people
- Sponsor
- Hamad Medical Corporation
Mild Cognitive Impairment
Exploratory Trial in Healthy Adults With Mild Cognitive Impairment,16-week Intervention With Mitocholine™
To evaluate the effect of 16-weeks consumption of Mitocholine on Executive Function and Homocysteine levels in a population experiencing Mild Cognitive Impairment.
- Trial name
- NCT05690724
- Where
- Ireland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mitocholine Ltd
Major Depressive Disorder
Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
To assess the efficacy of vortioxetine (10 to 20 mg/day) as adjunctive treatment to stable selective serotonin reuptake inhibitor (SSRI) dose versus stable SSRI monotherapy on cognitive performance (focusing on the aspect…
- Trial name
- NCT02279953
- Testing
- Vortioxetine 10-20 mg, SSRI
- Where
- 17 sites in Estonia, Finland and 3 more
- Volunteers
- 151 people
- Sponsor
- H. Lundbeck A/S
Risk Behavior, Cognitive Decline
Multidomain Intervention on Modifiable Lifestyle Risk Factors for Dementia Prevention
The overarching aim is to develop and deploy a multidomain intervention delivered on a mobile application to help middle-aged to older adults reduce their risk for dementia by improving a set of modifiable lifestyle risk factors…
- Trial name
- NCT05141578
- Testing
- Luci Coach Assisted Intervention
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- LuciLab
Dementia, Alzheimer Disease
Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in Patients With Alzheimer's Dementia Under Conditions of Daily Routine
The main objective of this non-interventional study was to document the long-term application of galantamine and nootropics (memory enhancing drugs) over a period of 1 year under conditions of daily routine.
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular
- Trial name
- NCT01009476
- Testing
- Galantamine, Nootropics (ginkgo biloba, nicergoline, piracetam, or others)
- Volunteers
- 1,134 people
- Sponsor
- Janssen-Cilag G.m.b.H
Infant Nutrition, Cognitive Development
Efficacy of a Nutrient Blend in Improving Neurocognitive and Behavioral Outcomes in Infants: a Randomized, Controlled, Intervention Study
The purpose of this study is to demonstrate the efficacy of the nutrient blend in a starter infant formula (IF) and follow up infant formula (FUF) in improving the neurocognitive and behavioural outcomes among formula-fed infants…
- Trial name
- NCT05310396
- Testing
- Experimental formula, Control Formula
- Where
- Philippines
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Cognitive Disorders
EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders
The purpose of this study is to determine the effectiveness of EGb 761® (Tanakan®) in Russian patients of middle age and younger, suffering from psycho-emotional symptoms added to cognitive disorders based on the improvement of…
- Trial name
- TAYPES (NCT02321475)
- Testing
- EGb761®
- Where
- 2 sites in Russia
- Volunteers
- 54 people
- Sponsor
- Ipsen
Autism Spectrum Disorder, Social Communication Disorder
To Evaluate the Efficacy and Safety of 'NDTx-01' in Patients With ASD or SCD
The purpose of this study is to demonstrate the superiority of the treatment of cognitive therapy software 'NDTx-01' compared to TAU (Treatment-As-Usual).
- Trial name
- NCT06446193
- Testing
- NDTx-01, TAU
- Where
- 5 sites in South Korea
- Volunteers
- 86 people
- Sponsor
- Neudive Inc.
Insomnia
WELT-REST: WELT Randomized Evaluation of Sleep Therapy
The goal of this clinical trial is to learn whether the SleepQ mobile app can help reduce insomnia symptoms in adults diagnosed with insomnia.
- Trial name
- WELT-REST (NCT07289217)
- Testing
- SleepQ Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I)
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- WELT corp
Parkinson's Disease
PIRLONG-PD Safety and Efficacy of Piribedil in Parkinson's Disease During Long Term Therapy
Non-Ergot Dopamine agonists are meanwhile the drugs of first-choice in the treatment of Parkinson's disease. The receptor profile of the non-ergot dopamine-agonist piribedil is unique.
- Trial name
- PIR-008/K (NCT01519856)
- Testing
- piribedil (Clarium)
- Where
- Germany
- Volunteers
- 908 people
- Sponsor
- Desitin Arzneimittel GmbH
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Major Depressive Disorder
Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder
This study aims at evaluating the effect of vortioxetine on cognitive dysfunction in major depressive disorder (MDD) patients with inadequate response to current antidepressant treatment.
- Trial name
- NCT02272517
- Testing
- Vortioxetine 10-20 mg, Escitalopram 10-20 mg
- Where
- 16 sites in Finland, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- H. Lundbeck A/S
Eating Disorders, Binge Eating
Study of Efficacy and Safety of WELT-ED for Eating Disorder (WCTP-ED-B-01)
The purpose of this clinical trial is to evaluate the safety and efficacy of a digital therapeutic device (WELT-ED) based on Cognitive Behavioral Therapy (CBT) for the treatment of eating disorders.
- Conditions
- Eating Disorders, Binge Eating, Binge-Eating Disorder
- Trial name
- NCT06294353
- Testing
- WELT-ED (CBT based DTx), Standard Treatment
- Where
- 2 sites in South Korea
- Volunteers
- 134 people
- Sponsor
- WELT corp
Cognitive Impairment, Memory Complaint
Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center
The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients…
- Conditions
- Cognitive Impairment, Memory Complaint, Clinical Investigation in Memory Centers
- Trial name
- DIALOG (NCT02221661)
- Volunteers
- 606 people
- Sponsor
- Diaxonhit